CD95 antigen mutations in hematopoietic malignancies

T. H. Landowski, L. Moscinski, R. Burke, I. Buyuksal, J. S. Painter, S. Goldstein, W. S. Dalton

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


The CD95 receptor, also known as Fas/Apo-1, is a member of the Tumor Necrosis Factor receptor (TNF-R) family of death receptors. Apoptosis mediated by CD95 plays a central role in maintaining homeostasis of the immune system. Dysregulation of the CD95 apoptotic pathway has been proposed as a mechanism of oncogenesis by providing a survival advantage to potentially malignant cells. This extended lifespan could allow the accumulation of further mutations leading to malignant transformation. Several mechanisms of resistance to CD95 mediated apoptosis have been identified, including reduced surface expression of the receptor, overexpression of anti-apoptotic molecules, and loss of function mutations. This review will focus on the potential role of the CD95-CD95 ligand system in the pathogenesis of hematological malignancies, with particular emphasis on recent work from our laboratory examining the expression of CD95 in B cell lymphomas. We demonstrate that CD95 mutations occur at low frequency in NHL tumors, however, surface expression of the CD95 protein varies with the subtype of lymphoma. Loss of surface CD95 is more likely to occur in lymphomas of aggressive histology, and is unrelated to the detection of CD95 mutations.

Original languageEnglish (US)
Pages (from-to)835-846
Number of pages12
JournalLeukemia and Lymphoma
Issue number5
StatePublished - Jan 1 2001


  • B-cell lymphomas
  • CD95 mutations
  • Fas/APO-I
  • Hematopoietic malignancy
  • TNF-R

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'CD95 antigen mutations in hematopoietic malignancies'. Together they form a unique fingerprint.

Cite this